DOC
SLIDES
Featured
Recent
Articles
Topics
Upload
Login
Sign Up
Featured
Recent
Articles
Topics
Upload
Login
Sign Up
Home
›
Search Results for "median response"
Search Results for 'median response'
median response published presentations and documents on DocSlides.
AML Elizabeth Ellent Some slides borrowed from Dr. Richard Stone and Dr. Naval
by bety
Daver. 7 + 3 . Thank you . Jk. . Basic Facts . Un...
Sipuleucel -T Survival Benefit
by calandra-battersby
Sipuleucel. -T was approved based on HR of 0.775 ...
Exploring Data:
by pasty-toler
Frequencies, . Central Tendency, Dispersion and S...
Best of ASCO GU Session Sandy Srinivas.MD
by experimentgoogle
Stanford University. Outline. Abstract #4. :. . I...
CD19-directed CAR T-cell therapy is feasible for older patients in the outpatient setting
by layla
. Andrew Ly. , Khaled Sanber, Hua-Ling Tsai, Angel...
Resurrecting response to
by alis
ruxolitinib : A Phase I study of ruxolitinib an...
Ambulance response times – what is the standard?
by unita
Dr Tim Kilner. P. rincipal Lecturer – paramedic ...
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma:
by Heartbreaker
Strategies for Incorporating Emerging. Immunothera...
Highlights in Multiple myeloma
by amber
How to treat. triple- or penta-refractory . Multip...
ESMO 2022 Congress Report
by paige
NSCLC, . gastric. . cancer. and . other. . soli...
Amyloidosis Update - 2021
by ImNotABaby
Ashutosh Wechalekar. Wild type ATTR is increasingl...
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
by hadly
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...
Dr. Gilles Salles Novel and Emerging Strategies for Diffuse Large B-Cell Lymphoma
by isabella2
Dr. Gilles SALLES. Chief . of. . the. . Lymphoma...
Updates on T-cell lymphoma
by grace3
Dr. Stefan K. Barta. University of Pennsylvania, U...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and
by scoopulachanel
Myeloma. 1. Safety and Efficacy of Daratumumab wit...
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
Relapsed and Refractory Myeloma
by jane-oiler
Ruben Niesvizky. Myeloma Center. Myelomacenter.or...
Summary of Cytogenetic
by cheryl-pisano
Response Among Cohorts . IM Failure + . DAS Resis...
Striking a Balance in Your Library Catalog: TMI vs. TLI
by giovanna-bartolotta
Karen Selden . Metadata Services Librarian. Unive...
Ibrutinib: Analysis of Pivotal Data
by alida-meadow
Richard R. Furman, MD. CLL Research Center. BCR-a...
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy
by bikersjoker
patients with . advanced breast . cancer and a ger...
Median Nerve Stimulation
by elyana
reflex (14). Polysynaptic reflexes are usually en...
Results of Phase II study of
by grace3
Durvalumab. in cancer patients with HIV-1 infecti...
What Can MRI Do for You?
by daisy
Yi Wang. Noninvasive . imaging. cellular. /macromo...
The Impending D eath of Cancer:
by elina
A Herculean Task. Emerging Therapies 2016. Ruemu E...
Abstract Background: Sporadic outbreaks of viral hepatitis and recent hepatitis A virus (HAV) outb
by jacey
Methods: . We analyzed the data of patients who pa...
COVID-19 outbreak in Italy: ICU response and patient characteristics
by ivy
Prof . Giacomo Grasselli. Associate Professor of ....
Stereotactic Radiosurgery in BrainCavernomas SingleCenter Experience
by lucy
Gökhan Yaprak, Alaattin Özen, Harun Demir, Fuzul...
x0000x0000 xAttxachexd xBottxom xBBoxx
by evans
Chimeric Antigen Receptor Tcell TherapyClinical Gu...
Validation of the NHS Scotland Employee Engagement Index
by sadie
Presentation to SWAG. Dr . Austyn. Snowden. NHSEE...
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
History, Definition & Terms associated with Chemotherapy
by evelyn
Mr. . Bhartendu. Vimal. Guest faculty-Asst. Prof....
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
by cadie
IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione...
Phase II studies of Nivolumab
by brianna
in patients with Advanced . Squamous. (SQ) or Non...
Evaluation of the Prognostic and Predictive Significance of Hepatocellular
by jideborn
Carcinoma Circulating Tumor Cells Expressing Progr...
Load More...